Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
CAMBRIDGE, Mass., March 27, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
CAMBRIDGE, Mass., March 07, 2024--Merrimack Reports Full Year 2023 Financial Results
Key Insights Significantly high institutional ownership implies Merrimack Pharmaceuticals' stock price is sensitive to...
CAMBRIDGE, Mass., February 13, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") reported that Ipsen, SA ("Ipsen") issued a press release today announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
CAMBRIDGE, Mass., November 02, 2023--Merrimack Reports Third Quarter 2023 Financial Results
Key Insights Significant control over Merrimack Pharmaceuticals by retail investors implies that the general public has...
CAMBRIDGE, Mass., August 03, 2023--Merrimack Reports Second Quarter 2023 Financial Results
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Merrimack...
CAMBRIDGE, Mass., May 04, 2023--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [("Merrimack" or the "Company")] today announced its first quarter 2023 financial results for the period ended March 31, 2023.